Page 103 - Heca News Today

Moderna’s shares crashed nearly 20% on Thursday, costing it $25 billion in market capitalization, after it cut its sales forecast for this year to $15 billion-$18 billion from $20 billion previously. It’s a reminder both of the success of boss Stéphane Bancel’s company and of its challenges.

Australia's High Court on Friday refused to hear an appeal that Johnson & Johnson sought to overturn a federal court ruling that its subsidiary, Ethicon, had sold defective pelvic mesh implants, a court spokesman said.

Kaisa Group Holdings Ltd and three of its units had their shares suspended from trading on Friday, a day after an affiliate missed a payment to onshore investors as China's snowballing property debt crisis jolts other developers.

The European Union's drug regulator said on Thursday it was in discussions with AstraZeneca over possible authorisation of booster doses of the drugmaker's COVID-19 vaccine, after it already gave the green light to mRNA booster shots.

Union leaders for 3,400 nurses and other medical staff at Kaiser Permanente in Oregon set a Nov. 15 strike deadline on Thursday, threatening a walkout they said would idle some 30,000 workers overall unless contract talks make suitable progress.

The death of a pregnant Polish woman has reignited debate over abortion in one of Europe's most devoutly Catholic countries, with activists saying she could still be alive if it were not for a near total ban on terminating pregnancies.

British scientists have identified a version of a gene that may be associated with double the risk of lung failure from COVID-19, a finding that provides new insights into why some people are more susceptible than othersto severe illness and which opens possibilities for targeted medicine.

The highest-ranking members of the Chinese Communist Party will gather in the coming days and are set to green-light another term for President Xi Jinping.

Roche's family owners have been saved from having to make an expensive offer for the rest of the pharmaceuticals giant's shares after its $20.7 billion deal to buy back Novartis's stake took them over a voting threshold.

The Democratic-controlled U.S. House of Representatives was expected to vote Friday on a sweeping, $1.75 trillion social-policy and climate package that accounts for much of Democratic President Joe Biden's domestic agenda.